Micurx Pharmaceuticals Inc.
- Address
- 950 Tower Lane Ste 390
Sponsor Overview
Specializations
Diabetic Foot Infections
Micurx Pharmaceuticals Inc. focuses on clinical research in diabetic foot infections, with attention to treatment options for adults affected by moderate to severe infection. The company’s funded work in this area centers on antibacterial therapy for complex soft tissue and wound-related infections associated with diabetes mellitus.
- Infection control in diabetic wounds
- Complicated skin and soft tissue infection
- Antibacterial treatment assessment
The sponsor’s research activity in this domain reflects interest in clinical outcomes relevant to infection resolution and tolerability in patients requiring both intravenous and oral treatment approaches.
Gram-Positive Bacterial Infections
The sponsor’s trial portfolio includes evaluation of therapies for infections commonly driven by Gram-positive bacteria, with particular relevance to organisms encountered in serious diabetic foot disease. This places emphasis on medical areas where resistant bacterial pathogens can complicate treatment selection.
- Antibacterial efficacy
- Resistant pathogen management
- Serious bacterial infection treatment
Research in this field supports assessment of clinical response in settings where infection burden and bacterial susceptibility are central therapeutic concerns.
Hospital and Outpatient Antimicrobial Therapy
Micurx Pharmaceuticals Inc. is involved in clinical evaluation of antimicrobial therapy spanning both intravenous and oral administration, reflecting interest in treatment pathways that extend across acute care and follow-up settings. This area is especially relevant for infections that require step-down therapy.
- IV-to-oral treatment strategies
- Systemic antibacterial therapy
- Treatment tolerability
The sponsor’s research focus in this domain aligns with practical management of infection in patients needing sustained antimicrobial coverage.
Safety and Clinical Response Assessment
The funded trial activity places strong emphasis on safety, tolerability, and clinical response in adults with serious infection. These endpoints are important in therapeutic areas where adverse effects and treatment effectiveness must be balanced carefully.
- Clinical response evaluation
- Medication safety
- Treatment tolerability
This area of interest supports development of infection treatments suitable for patients with substantial underlying disease burden, including those with diabetes-related complications.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections |  Bulgaria Croatia Czechia Estonia France Greece Hungary Italy Latvia Lithuania Poland Portugal Romania Slovakia Spain | Recruiting |
Data & Insights
This sponsor works with 5 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 57 sites across their trial portfolio.
Therapeutic Focus
- 1.Bacterial Infections and Mycoses1 trial180 other sponsors
Partnered Research Centres
57 centres- Address
- Mudr. Pribulu 412/4, 089 01 Svidník
- Address
- Via Sergio Pansini 5, 80131 Naples
- Address
- Via Pozzuolo 330, 33100 Udine
- Address
- Lankos G. 1, Kauno M. Sav., 50168 Kaunas
- Address
- 155 Rue Du President Coty, Bp 40619, 59208 Tourcoing
- Address
- 4 Place Du Professeur Robert Debre, Bp 40026, 30029 Nîmes
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Micurx Pharmaceuticals Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.